Key Takeaways:
(P1) Eli Lilly is betting up to $2.25 billion on artificial intelligence to solve one of the biggest challenges in genetic medicine, striking a multi-program collaboration with startup Profluent to design novel gene-editing tools.
(P2) "Kilobase-scale DNA editing remains a holy grail in genetic medicine," Ali Madani, co-founder and CEO of Profluent, said in a statement. "Our work with Lilly is aimed at unlocking these therapeutics previously thought impossible. We believe only AI can create the designer recombinases needed to precisely target any location in the genome."
(P3) The partnership, announced Tuesday, will focus on creating bespoke enzymes called recombinases capable of inserting large stretches of DNA—even entire genes—at specific locations in a patient's genome. While specific financial terms beyond the total potential value were not disclosed, the deal gives Lilly an exclusive license to advance and commercialize any resulting therapies. The move is part of a broader strategic push by Lilly into genetic medicine, which includes the establishment of a new research center in Boston and several acquisitions in the gene therapy space.
(P4) At stake is the ability to treat a wide range of genetic diseases that are currently intractable due to their genetic heterogeneity. Unlike CRISPR-based systems, which are often focused on single-gene mutations, the technology sought by Lilly and Profluent could address conditions caused by multiple different mutations across patient populations. The partnership validates Profluent's AI-driven approach and signals a growing demand from major pharmaceutical firms for advanced AI to accelerate drug discovery.
The collaboration aims to move beyond the limitations of conventional gene editing, which often relies on discovering naturally occurring enzymes that happen to work for a specific task. Profluent's platform, by contrast, uses large-scale AI models to design proteins from the ground up, creating custom enzymes programmed to execute precise edits at exact genomic locations. This could significantly expand the scope and scalability of programmable gene editing therapeutics.
For Eli Lilly, the deal reinforces its innovation pipeline as it enjoys record revenues from its blockbuster obesity and diabetes drugs. The company's increased focus on the high-growth gene therapy market is a strategic effort to build its next generation of revenue drivers. The field is rapidly advancing, with recent successes like Vertex Pharmaceutical’s Casgevy, a CRISPR-based treatment for sickle cell disease, and a promising in-vivo treatment from Intellia Therapeutics for a rare genetic disorder, demonstrating the transformative potential of gene-editing technologies.
By partnering with an AI-native firm like Profluent, Lilly is effectively outsourcing a highly specialized and computationally intensive part of the discovery process. This allows the pharmaceutical giant to combine its vast clinical development and commercialization capabilities with cutting-edge AI, a model that is becoming increasingly prevalent in the industry.
This article is for informational purposes only and does not constitute investment advice.
